Annovis Bio is down -12.1%, or -$1.12 to $8.16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Shares Surge on Positive Parkinson’s Study Data
- Annovis Bio’s buntanetap shows efficacy in Phase 3 Parkinson’s study
- Annovis Bio files provisional patent for manufacturing process of buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap